Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Cancer Research
|
June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
A Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
The Oncologist
|
May 21, 2010
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
Dan G Duda, Christopher G Willett, Marek Ancukiewicz, et al.
Future Oncology (London, England)
|
August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer
David M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
The International Journal of Biological Markers
|
September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy
Rimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
David M O'Malley, Maryna Neffa, Bradley J Monk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Andrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Cancer Research
|
October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer
Lei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
The Oncologist
|
July 30, 2010
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer
Christopher G Willett, Dan G Duda, Marek Ancukiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Lung dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation using three-dimensional conformal radiotherapy
Abram Recht, Marek Ancukiewicz, Mohamed A Alm El-Din, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 16, 2013
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer
Jennifer Y Wo, Harvey J Mamon, Cristina R Ferrone, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Cancer Research
|
June 25, 2009
A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients
A Gregory Sorensen, Tracy T Batchelor, Wei-Ting Zhang, et al.
The Oncologist
|
May 21, 2010
Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer
Dan G Duda, Christopher G Willett, Marek Ancukiewicz, et al.
Future Oncology (London, England)
|
August 19, 2021
RaPiDS (GOG-3028): randomized Phase II study of balstilimab alone or in combination with zalifrelimab in cervical cancer
David M O'Malley, Leslie M Randall, Camille Gunderson Jackson, et al.
The International Journal of Biological Markers
|
September 28, 2012
Circulating tumor cells as predictors of response and failure in breast cancer patients treated with preoperative chemotherapy
Rimoun R Boutrus, Rita F Abi Raad, Irene Kuter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 21, 2021
Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study
David M O'Malley, Maryna Neffa, Bradley J Monk, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 4, 2013
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer
Andrew X Zhu, Richard S Finn, Mary Mulcahy, et al.
Cancer Research
|
October 15, 2009
Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer
Lei Xu, Dan G Duda, Emmanuelle di Tomaso, et al.
The Oncologist
|
July 30, 2010
A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer
Christopher G Willett, Dan G Duda, Marek Ancukiewicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2009
Lung dose-volume parameters and the risk of pneumonitis for patients treated with accelerated partial-breast irradiation using three-dimensional conformal radiotherapy
Abram Recht, Marek Ancukiewicz, Mohamed A Alm El-Din, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
November 16, 2013
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer
Jennifer Y Wo, Harvey J Mamon, Cristina R Ferrone, et al.
Page
of 9